Sitosterolemia Extension Study - Tabular View

Tracking Information
First Received Date ^ICMJE	September 23, 2004
Last Updated Date	May 17, 2006
Start Date ^ICMJE	March 2001
Current Primary Outcome Measures ^ICMJE (submitted: February 27, 2006)	To assess the percent change relative to baseline in plasma sitosterol concentration after long-term treatment with MK-0653 10 mg/day.
Original Primary Outcome Measures ^ICMJE (submitted: January 13, 2006)	Plasma sitosterol levels after 52 weeks
Change History	Complete list of historical versions of study NCT00092807 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: February 27, 2006)	Assess the percent change relative to baseline in LDL-C/plasma campesterol concentrations, and safety and tolerability after long-term treatment with MK-0653 10 mg/day in patients with homozygous sitosterolemia
Original Secondary Outcome Measures ^ICMJE (submitted: January 13, 2006)	Plasma LDL-C and plasma campesterol. Safety and tolerability

Descriptive Information
Brief Title ^ICMJE	Sitosterolemia Extension Study
Official Title ^ICMJE	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension
Brief Summary	This is an extension study for patients having unusually high absorption of non-cholesterol sterols, resulting in heart-related diseases. This study will evaluate the long term safety and the ability to lower cholesterol levels with an investigational drug.
Detailed Description	The duration of treatment is 52 weeks.
Study Phase	Phase III
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment, Safety Study
Condition ^ICMJE	Lipid Metabolism, Inborn Errors Heart Disease
Intervention ^ICMJE	Drug: MK0653, ezetimibe Drug: Comparator: placebo
Study Arms / Comparison Groups
Publications *	Salen G, von Bergmann K, Lutjohann D, Kwiterovich P, Kane J, Patel SB, Musliner T, Stein P, Musser B; Multicenter Sitosterolemia Study Group. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation. 2004 Mar 2;109(8):966-71. Epub 2004 Feb 09.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE	14
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Patients with elevated sitosterol levels while taking current medication Exclusion Criteria: Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.
Gender	Both
Ages	10 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States
Expanded Access Status

Administrative Information
NCT ID ^ICMJE	NCT00092807
Responsible Party
Study ID Numbers ^ICMJE	2004_032
Study Sponsor ^ICMJE	Merck
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Merck
Verification Date	October 2005
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP